Ignite Creation Date:
2024-05-06 @ 2:26 PM
Last Modification Date:
2024-10-26 @ 1:30 PM
Study NCT ID:
NCT04310592
Status:
RECRUITING
Last Update Posted:
2023-02-16
First Post:
2020-03-12
Brief Title:
Natural Killer Cell CYNK-001 Infusions in Adults With AML
Sponsor:
Celularity Incorporated
Organization:
Celularity Incorporated
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Refractory AML |
| Leukemia |
| Leukemia Myeloid |
| Leukemia Myeloid Acute |
| Neoplasms by Histologic Type |
| Neoplasms |
| Immunosuppressive Agents |
| Immunologic Factors |
| Physiological Effects of Drugs |
| Alkylating Agents |
| Antimetabolites Antineoplastic |
| Antiviral Agents |
| Analgesics Non-narcotic |
| Anti-infective Agents |
| Analgesics |
| Peripheral Nervous System Agents |
| Hematologic Diseases |
| Hematologic Neoplasms |
| Leukemia in Remission |
| Relapsed Adult AML |
Keywords:
| Name | View |
|---|---|
| refractory AML | View |
| CYNK-001 | View |
| Acute Myeloid Leukemia | View |
| Acute Myelogenous Leukemia | View |
| allogeneic | View |
| allogeneic stem cell transplant | View |
| AML | View |
| cell therapy | View |
| cyclophosphamide | View |
| fludarabine | View |
| minimal residual disease | View |
| MRD | View |
| newly diagnosed AML | View |
| newly diagnosed acute myeloid leukemia | View |
| NK cells | View |
| natural killer cells | View |
| fludarabine phosphate | View |
| antineoplastic agents alkylating | View |
| molecular mechanisms of pharmacological action | View |
| relapsed AML | View |